GlassScriptPhysician profile
Smita Ranjan
NPI 1831478114
$91,828.13
in general payments reported to CMS, 2019-2025
46 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20K · 2022: $20K · 2023: $24K · 2024: $12K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Food and Beverage: $6,877 · Consulting Fee: $4,296 · Travel and Lodging: $3,899 · Education: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36,442.00 |
| Food and Beverage | $6,876.74 |
| Consulting Fee | $4,296.00 |
| Travel and Lodging | $3,898.60 |
| Education | $398.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $66,584.21 | 2021-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $17,723.86 | 2021-2025 | Imfinzi, Tagrisso, Datroway |
| Celgene Corporation | $1,615.61 | 2022-2025 | Reblozyl, Opdualag, Opdivo |
| Merck Sharp & Dohme LLC | $1,028.50 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Amgen INC. | $389.58 | 2021-2023 | Xgeva, Vectibix, Lumakras |
| Daiichi Sankyo INC. | $371.97 | 2022-2025 | Enhertu, Datroway |
| Incyte Corporation | $326.66 | 2021-2025 | Jakafi, Pemazyre, Monjuvi |
| Regeneron Healthcare Solutions, INC. | $322.35 | 2023-2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $263.10 | 2021-2025 | |
| Genzyme Corporation | $250.51 | 2021-2025 | |
| Array Biopharma INC | $237.39 | 2023-2025 | Mektovi, Braftovi, Lorbrena |
| Seagen INC. | $225.00 | 2023-2024 | Tukysa |
| Pfizer INC. | $205.11 | 2022-2025 | |
| Janssen Biotech, INC. | $204.68 | 2022-2025 | Rybrevant, Erleada, Tecvayli |
| Takeda Pharmaceuticals U.S.A., INC. | $193.94 | 2023-2024 | Ninlaro, Alunbrig |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $175.59 | 2021-2024 | Jaypirca, Verzenio, Retevmo |
| Novocure INC. | $150.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $146.39 | 2023-2025 | |
| Eisai INC. | $138.87 | 2022-2024 | |
| Genentech USA, INC. | $131.14 | 2023-2025 | Tecentriq, Tecentriq Hybreza, Itovebi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.63 | 2021-2025 | Gilotrif |
| Iovance Biotherapeutics, INC. | $114.39 | 2025 | Amtagvi |
| Sumitomo Pharma America, INC. | $109.45 | 2023-2025 | Orgovyx |
| Rigel Pharmaceuticals, INC. | $96.80 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Mirati Therapeutics, INC. | $84.09 | 2023 | Krazati |
| Stemline Therapeutics INC. | $80.43 | 2024-2025 | Orserdu |
| Aveo Pharmaceuticals, INC. | $58.51 | 2024-2025 | |
| Glaxosmithkline, LLC. | $54.73 | 2022-2025 | Ojjaara, Blenrep |
| Gilead Sciences, INC. | $48.19 | 2025 | Trodelvy |
| Ipsen Biopharmaceuticals, INC | $43.04 | 2024-2025 | Onivyde |
| Apellis Pharmaceuticals, INC. | $32.17 | 2022-2023 | Empaveli |
| Pharming Healthcare, INC. | $30.05 | 2023 | Ruconest |
| Alexion Pharmaceuticals, INC. | $27.49 | 2025 | Ultomiris |
| Sun Pharmaceutical Industries INC. | $22.96 | 2023 | Yonsa, Odomzo |
| Agios Pharmaceuticals, INC. | $22.84 | 2024 | |
| Sobi, INC | $20.78 | 2024 | |
| Coherus Oncology, INC. | $20.49 | 2023 | |
| Foundation Medicine, INC. | $19.72 | 2023 | Foundationone Cdx |
| Cumberland Pharmaceuticals, INC. | $19.39 | 2025 | Sancuso |
| Pharmacyclics LLC, An Abbvie Company | $19.30 | 2023 | Imbruvica |
| Pharmacosmos Therapeutics INC. | $18.92 | 2024 | Cosela |
| G1 Therapeutics, INC. | $17.79 | 2023 | Cosela |
| Tersera Therapeutics LLC | $17.54 | 2024 | Zoladex |
| Springworks Therapeutics, INC. | $16.25 | 2025 | Gomekli |
| Adc Therapeutics America, INC. | $15.22 | 2023 | |
| Kite Pharma, INC. | $13.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smita Ranjan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.